While other SGLT2 inhibitors have enjoyed the spotlight regarding their efficacy against heart failure, the hypothesis of this study is that ertugliflozin also provides a significant cardiovascular benefit, an effect which it would share with the other drugs in the SGLT2 inhibitor class. This evidence concerns the gene SLC5A2 and heart failure.